Curis
CRIS
$14.60
Share price
-1.15%
Change (1 day)
1,725.00%
Change (1 year)
Categories
Operating Margin for Curis (CRIS)
Operating Margin as of April 2024 (TTM): -426.66%
According to Curis's latest financial reports and stock price the company's current Operating Margin is -426.66%. At the end of 2021 the company had an Operating Margin of -426.67%.
Operating Margin history for Curis from 2001 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -426.67% | 54.57% |
| 2020 | -276.03% | -14.08% |
| 2019 | -321.28% | 2.85% |
| 2018 | -312.39% | -42.01% |
| 2017 | -538.66% | -32.88% |
| 2016 | -802.59% | 7.21% |
| 2015 | -748.64% | 293.46% |
| 2014 | -190.27% | 131.64% |
| 2013 | -82.14% | -15.08% |
| 2012 | -96.73% | 98.26% |
| 2011 | -48.79% | 38.46% |
| 2010 | -35.24% | -69.87% |
| 2009 | -116.94% | -25.43% |
| 2008 | -156.81% | 206.87% |
| 2007 | -51.10% | -24.1% |
| 2006 | -67.32% | -74.53% |
| 2005 | -264.35% | -16.21% |
| 2004 | -315.48% | 251.65% |
| 2003 | -89.72% | -78.26% |
| 2002 | -412.69% | -94.52% |
| 2001 | -7,534.60% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 34.61% | -108.11% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 19.24% | -104.51% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | -109.76% | -74.27% | 🇺🇸 USA |
 Exelixis EXEL | 11.86% | -102.78% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -1,520.92% | 256.47% | 🇺🇸 USA |
 Cel-Sci
CVM | -5,975.84% | 1,300.61% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 17.53% | -104.11% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.